HUS2300022I1 - Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz - Google Patents

Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz

Info

Publication number: HUS2300022I1
Authority: HU; Hungary
Prior art keywords: vaccines; preparations; methods; dengue virus; chimeric constructs
Prior art date: 2013-03-15

Application number

HUS2300022C

Other languages

English (en)

Original Assignee

Takeda Vaccines Inc

30341 Atlanta 4770 Buford Highway Tech Transfer Office K79

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2023-06-20

Publication date

2023-08-28

2023-06-20 Application filed by Takeda Vaccines Inc, 30341 Atlanta 4770 Buford Highway Tech Transfer Office K79 filed Critical Takeda Vaccines Inc

2023-08-28 Publication of HUS2300022I1 publication Critical patent/HUS2300022I1/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Oncology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HUS2300022C 2013-03-15 2023-06-20 Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz HUS2300022I1 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361800204P	2013-03-15	2013-03-15
EP19168475.2A EP3539565B1 (en)	2013-03-15	2014-03-12	Compositions and methods for dengue virus chimeric constructs in vaccines

Publications (1)

Publication Number	Publication Date
HUS2300022I1 true HUS2300022I1 (hu)	2023-08-28

Family

ID=50678274

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE19168475A HUE061507T2 (hu)	2013-03-15	2014-03-12	Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz
HUS2300022C HUS2300022I1 (hu)	2013-03-15	2023-06-20	Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE19168475A HUE061507T2 (hu)	2013-03-15	2014-03-12	Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz

Country Status (32)

Country	Link
US (6)	US9783579B2 (hu)
EP (5)	EP4183411A1 (hu)
JP (2)	JP6818548B2 (hu)
KR (4)	KR102626270B1 (hu)
CN (5)	CN113637693B (hu)
AR (4)	AR095598A1 (hu)
AU (2)	AU2014235476B2 (hu)
CA (3)	CA3177574A1 (hu)
CR (1)	CR20150569A (hu)
DK (1)	DK4129330T5 (hu)
DO (1)	DOP2015000232A (hu)
EC (1)	ECSP23013715A (hu)
ES (2)	ES2965652T3 (hu)
FI (2)	FI3539565T3 (hu)
FR (1)	FR22C1064I2 (hu)
HR (1)	HRP20231581T1 (hu)
HU (2)	HUE061507T2 (hu)
LT (2)	LT4129330T (hu)
MX (5)	MX374519B (hu)
MY (1)	MY187796A (hu)
NL (1)	NL301223I2 (hu)
NO (1)	NO2023026I1 (hu)
NZ (1)	NZ630869A (hu)
PE (2)	PE20160027A1 (hu)
PH (1)	PH12015502120B1 (hu)
PL (1)	PL3539565T3 (hu)
PT (1)	PT3539565T (hu)
SG (3)	SG10201913387XA (hu)
SI (1)	SI4129330T1 (hu)
TW (3)	TWI894248B (hu)
UY (1)	UY35489A (hu)
WO (1)	WO2014150939A2 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20231581T1 (hr) *	2013-03-15	2024-03-15	Takeda Vaccines, Inc.	Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
US10004795B2 (en) *	2015-09-08	2018-06-26	Fundacao Butantan	Process for preparing an attenuated tetravalent dengue vaccine
SG11201804317YA (en) *	2015-11-27	2018-06-28	The Chemo Sero Therapeutic Res Institute	Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens
US11007261B2 (en) *	2016-04-13	2021-05-18	Takeda Vaccines, Inc.	Compositions and methods of vaccination against dengue virus in children and young adults
US11464815B2 (en)	2018-09-05	2022-10-11	Takeda Vaccines, Inc.	Dengue vaccine unit dose and administration thereof
US11426461B2 (en)	2018-09-05	2022-08-30	Takeda Vaccines, Inc.	Methods for preventing dengue and hepatitis A
KR20210071979A (ko)	2018-09-05	2021-06-16	다케다 백신즈 인코포레이티드	뎅기열 백신 단위 용량 및 이의 투여
US20240076631A2 (en)	2020-02-27	2024-03-07	Takeda Vaccines, Inc.	Method for removing host cell dna from virus preparation
WO2021173597A1 (en) *	2020-02-28	2021-09-02	Merck Sharp & Dohme Corp.	Dengue serotype specific rt-pcr multiplex assay
EP3892737A1 (en) *	2020-04-09	2021-10-13	Takeda Vaccines, Inc.	Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147337A2 (en)	2022-01-25	2023-08-03	Takeda Vaccines, Inc.	Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en)	2022-02-15	2025-06-05	Takeda Vaccines, Inc.	Dengue vaccine batch mixing process
WO2023215383A1 (en)	2022-05-04	2023-11-09	Takeda Vaccines, Inc.	Computer-based determination of flavivirus infectivity
WO2024086681A1 (en) *	2022-10-20	2024-04-25	Takeda Vaccines, Inc.	A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
CN120225693A (zh)	2022-11-18	2025-06-27	武田疫苗股份有限公司	测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
CN120529951A (zh)	2022-11-29	2025-08-22	武田疫苗股份有限公司	大规模黄病毒疫苗生产和制造
WO2025122855A1 (en)	2023-12-08	2025-06-12	Takeda Vaccines, Inc.	A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5276941A (en)	1975-12-23	1977-06-28	Ito Masato	Method of conversing infrared rays
US4810092A (en)	1986-02-21	1989-03-07	Midac Corporation	Economical spectrometer unit having simplified structure
JPH0768267B2 (ja)	1986-06-05	1995-07-26	財団法人阪大微生物病研究会	フラビウイルス抗原
JPH084508B2 (ja)	1987-09-16	1996-01-24	国立予防衛生研究所長	組み換えワクチニアウイルス
JP2511494B2 (ja)	1988-05-12	1996-06-26	善治松浦	日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en)	1988-07-14	2001-02-06	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en)	1988-08-20	1990-03-19	Us Health	Recombinant vaccinia virus for prevention of disease caused by flavivirus
MY109299A (en)	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en)	1990-08-15	1996-05-07	Virogenetics Corporation	Flavivirus recombinant poxvirus vaccine
US5494671A (en)	1990-08-27	1996-02-27	The United States Of America As Represented By The Department Of Health And Human Services	C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
CA2116980C (en)	1991-09-19	2006-06-06	Ching-Juh Lai	Chimeric and/or growth-restricted flaviviruses
JPH05276941A (ja)	1992-02-28	1993-10-26	Nippon Zeon Co Ltd	フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
PT836482E (pt)	1995-05-24	2003-02-28	Hawaii Biotech Group	Vacina subunitaria contra infeccao por flavirus
AU6093296A (en) *	1995-06-07	1996-12-30	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Infectious dengue 2 virus pdk-53 as quadravalent vaccine
DK0977587T3 (da)	1997-02-28	2005-10-17	Acambis Inc	Kimære flavivirus-vacciner
RU2208635C2 (ru)	1997-10-08	2003-07-20	ЗЕ ГАВЕРМЕНТ ОФ ЗЕ ЮНАЙТЕД СТАЙТС ОФ АМЕРИКА, репрезентед бай ЗЕ СЕКРЕТЕРИ, ДЕПАРТМЕНТ ОФ ХЕЛС ЭНД ХЬЮМЭН СЕРВАЙСЕЗ	Днк-конструкт жизнеспособного химерного рекомбинантного флавивируса, вакцина против вируса клещевого энцефалита, способ предотвращения инфицирования млекопитающего вирусом клещевого энцефалита
DE29810020U1 (de)	1998-06-04	1998-09-24	Siemens AG, 80333 München	Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien
DE69934583T2 (de)	1998-06-04	2007-10-04	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
AU1813901A (en) *	1999-12-01	2001-06-12	Oravax, Inc	Chimeric flavivirus vaccines
CA2398872C (en)	2000-02-16	2018-03-20	Richard M. Kinney	Avirulent, immunogenic flavivirus chimeras
ES2315221T3 (es) *	2000-05-30	2009-04-01	Mahidol University	Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
CA2440593A1 (en)	2001-03-12	2002-09-19	Yale University	Compositions and methods comprising west nile virus polypeptides
BRPI0613328A2 (pt) *	2005-06-17	2011-01-04	Sanofi Pasteur	cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna
KR20080018271A (ko) *	2005-06-17	2008-02-27	사노피 파스퇴르	약독화된 뎅기 혈청형 2 균주
KR20070017759A (ko)	2005-08-08	2007-02-13	삼성전자주식회사	초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
US20080193477A1 (en) *	2005-08-10	2008-08-14	Acambis Inc.	Vaccination Against Dengue Virus Infection
US7968102B2 (en) *	2006-01-13	2011-06-28	Sanofi Pasteur S.A.	Dengue chimeric viruses
LT2589602T (lt) *	2006-08-15	2016-10-10	The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health	Dengė viruso vakcinos komponentų gavimas
US8541377B2 (en)	2007-07-13	2013-09-24	Florida Gulf Coast University	Optimized dengue virus entry inhibitory peptide (DN81)
AU2009241354B2 (en) *	2008-04-30	2014-06-12	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Chimeric West Nile/Dengue viruses
SG157244A1 (en)	2008-05-15	2009-12-29	Mp Biomedicals Asia Pacific Pte Ltd	Point of care test for the detection of exposure or immunity to dengue virus
WO2010085358A2 (en) *	2009-01-23	2010-07-29	The Board Of Regents Of The University Of Texas System	Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
CN107913406A (zh)	2009-06-01	2018-04-17	武田疫苗公司	施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en)	2009-06-01	2015-03-03	Takeda Vaccines, Inc.	Compositions and methods for rapid immunization against dengue virus
CN101560520A (zh) *	2009-06-04	2009-10-21	中国疾病预防控制中心病毒病预防控制所	乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) *	2009-10-01	2021-05-25	Fundacao Oswaldo Cruz	composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en)	2010-02-04	2011-08-10	Sanofi Pasteur	Immunization compositions and methods
NZ630831A (en)	2012-06-10	2019-02-22	Takeda Vaccines Inc	Compositions and methods for administration of vaccines against dengue virus
SG10201912291YA (en)	2012-07-24	2020-02-27	Sanofi Pasteur	Vaccine compositions
KR20150036593A (ko)	2012-07-24	2015-04-07	사노피 파스퇴르	뎅기열 바이러스 감염 예방용 백신 조성물
TW201920677A (zh) *	2012-11-08	2019-06-01	美商武田疫苗股份有限公司	登革熱病毒血清型４型之建構物的組成物、方法及用途
CA2933472A1 (en) *	2012-12-14	2014-06-19	Takeda Vaccines, Inc.	Compositions, methods of administration and uses for trivalent dengue virus formulations
HRP20231581T1 (hr)	2013-03-15	2024-03-15	Takeda Vaccines, Inc.	Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
TWI852899B (zh)	2014-09-02	2024-08-21	法商賽諾菲巴斯德公司	疫苗組合物
WO2017005654A1 (en)	2015-07-03	2017-01-12	Sanofi Pasteur	Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
US10857222B2 (en)	2015-07-03	2020-12-08	Sanofi Pasteur	Concomitant dengue and yellow fever vaccination
US10004795B2 (en)	2015-09-08	2018-06-26	Fundacao Butantan	Process for preparing an attenuated tetravalent dengue vaccine
US11007261B2 (en)	2016-04-13	2021-05-18	Takeda Vaccines, Inc.	Compositions and methods of vaccination against dengue virus in children and young adults
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7261239B2 (ja)	2017-10-16	2023-04-19	セラムインスティチュートオブインディアプライベイトリミテッド	弱毒生組換えフラビウイルスなどから成る安定したワクチン組成物およびその調製方法
US11464815B2 (en)	2018-09-05	2022-10-11	Takeda Vaccines, Inc.	Dengue vaccine unit dose and administration thereof
KR20210071979A (ko)	2018-09-05	2021-06-16	다케다 백신즈 인코포레이티드	뎅기열 백신 단위 용량 및 이의 투여
EP3892737A1 (en)	2020-04-09	2021-10-13	Takeda Vaccines, Inc.	Qualitative and quantitative determination of single virus haplotypes in complex samples

2014
- 2014-03-12 HR HRP20231581TT patent/HRP20231581T1/hr unknown
- 2014-03-12 PL PL19168475.2T patent/PL3539565T3/pl unknown
- 2014-03-12 CA CA3177574A patent/CA3177574A1/en active Pending
- 2014-03-12 CN CN202110718694.2A patent/CN113637693B/zh active Active
- 2014-03-12 JP JP2016501585A patent/JP6818548B2/ja active Active
- 2014-03-12 KR KR1020227013084A patent/KR102626270B1/ko active Active
- 2014-03-12 AU AU2014235476A patent/AU2014235476B2/en active Active
- 2014-03-12 CN CN202110723336.0A patent/CN113637086B/zh active Active
- 2014-03-12 DK DK22182269.5T patent/DK4129330T5/da active
- 2014-03-12 CA CA3166063A patent/CA3166063A1/en active Pending
- 2014-03-12 SG SG10201913387XA patent/SG10201913387XA/en unknown
- 2014-03-12 ES ES22182269T patent/ES2965652T3/es active Active
- 2014-03-12 WO PCT/US2014/024603 patent/WO2014150939A2/en not_active Ceased
- 2014-03-12 EP EP22204593.2A patent/EP4183411A1/en active Pending
- 2014-03-12 SG SG11201507460PA patent/SG11201507460PA/en unknown
- 2014-03-12 ES ES20154012T patent/ES2933970T3/es active Active
- 2014-03-12 LT LTEP22182269.5T patent/LT4129330T/lt unknown
- 2014-03-12 KR KR1020257006481A patent/KR20250033325A/ko active Pending
- 2014-03-12 SG SG10201913435TA patent/SG10201913435TA/en unknown
- 2014-03-12 SI SI201432055T patent/SI4129330T1/sl unknown
- 2014-03-12 CN CN201480028001.5A patent/CN105451763B/zh active Active
- 2014-03-12 KR KR1020247001384A patent/KR102775714B1/ko active Active
- 2014-03-12 MY MYPI2015002317A patent/MY187796A/en unknown
- 2014-03-12 CN CN202010617988.1A patent/CN111778263B/zh active Active
- 2014-03-12 CN CN202110718703.8A patent/CN113637694B/zh active Active
- 2014-03-12 HU HUE19168475A patent/HUE061507T2/hu unknown
- 2014-03-12 CA CA2903231A patent/CA2903231C/en active Active
- 2014-03-12 EP EP22182269.5A patent/EP4129330B1/en active Active
- 2014-03-12 EP EP20154012.7A patent/EP3689374B1/en active Active
- 2014-03-12 EP EP14722014.9A patent/EP2968516B1/en active Active
- 2014-03-12 NZ NZ630869A patent/NZ630869A/en unknown
- 2014-03-12 PT PT191684752T patent/PT3539565T/pt unknown
- 2014-03-12 MX MX2015012893A patent/MX374519B/es active IP Right Grant
- 2014-03-12 EP EP19168475.2A patent/EP3539565B1/en active Active
- 2014-03-12 PE PE2015001953A patent/PE20160027A1/es unknown
- 2014-03-12 PE PE2021000217A patent/PE20211814A1/es unknown
- 2014-03-12 KR KR1020157029897A patent/KR102389908B1/ko active Active
- 2014-03-12 FI FIEP19168475.2T patent/FI3539565T3/fi active
- 2014-03-12 PH PH1/2015/502120A patent/PH12015502120B1/en unknown
- 2014-03-13 US US14/209,808 patent/US9783579B2/en active Active
- 2014-03-14 TW TW110111747A patent/TWI894248B/zh active
- 2014-03-14 TW TW108114540A patent/TWI726312B/zh active
- 2014-03-14 TW TW103109624A patent/TWI733646B/zh active
- 2014-03-17 AR ARP140101223A patent/AR095598A1/es active IP Right Grant
- 2014-03-17 UY UY35489A patent/UY35489A/es active IP Right Grant
2015
- 2015-09-11 DO DO2015000232A patent/DOP2015000232A/es unknown
- 2015-09-14 MX MX2023000353A patent/MX2023000353A/es unknown
- 2015-09-14 MX MX2019003602A patent/MX2019003602A/es unknown
- 2015-09-14 MX MX2023000354A patent/MX2023000354A/es unknown
- 2015-09-14 MX MX2023000349A patent/MX2023000349A/es unknown
- 2015-10-15 CR CR20150569A patent/CR20150569A/es unknown
2017
- 2017-04-20 US US15/492,981 patent/US10449231B2/en active Active
2019
- 2019-06-05 JP JP2019105307A patent/JP7050031B2/ja active Active
- 2019-08-16 AU AU2019216724A patent/AU2019216724C1/en active Active
- 2019-09-05 US US16/561,755 patent/US20200061151A1/en not_active Abandoned
2021
- 2021-09-17 US US17/478,537 patent/US12186363B2/en active Active
- 2021-10-06 AR ARP210102772A patent/AR123702A2/es unknown
2022
- 2022-12-12 US US18/064,775 patent/US11931399B2/en active Active
- 2022-12-16 FR FR22C1064C patent/FR22C1064I2/fr active Active
2023
- 2023-02-24 EC ECSENADI202313715A patent/ECSP23013715A/es unknown
- 2023-03-08 NL NL301223C patent/NL301223I2/nl unknown
- 2023-06-20 HU HUS2300022C patent/HUS2300022I1/hu unknown
- 2023-06-27 FI FIC20230021C patent/FIC20230021I1/fi unknown
- 2023-07-04 NO NO2023026C patent/NO2023026I1/no unknown
2024
- 2024-02-28 AR ARP240100498A patent/AR132009A2/es unknown
- 2024-03-05 LT LTPA2024503C patent/LTPA2024503I1/lt unknown
- 2024-07-10 US US18/768,774 patent/US20250018006A1/en active Pending
- 2024-07-16 AR ARP240101841A patent/AR133264A2/es unknown

Also Published As

Publication number	Publication date
US12186363B2 (en)	2025-01-07
CA2903231A1 (en)	2014-09-25
JP6818548B2 (ja)	2021-01-20
WO2014150939A3 (en)	2014-12-31
KR20250033325A (ko)	2025-03-07
AU2019216724A1 (en)	2019-09-05
MY187796A (en)	2021-10-24
CN113637693B (zh)	2024-10-11
PE20160027A1 (es)	2016-01-28
US9783579B2 (en)	2017-10-10
NL301223I2 (nl)	2023-07-26
AU2019216724B2 (en)	2021-03-04
EP3539565B1 (en)	2023-01-11
SI4129330T1 (sl)	2024-02-29
NZ735336A (en)	2021-04-30
EP3539565A1 (en)	2019-09-18
SG11201507460PA (en)	2015-10-29
KR20220054892A (ko)	2022-05-03
US20170290884A1 (en)	2017-10-12
PE20211814A1 (es)	2021-09-14
TWI733646B (zh)	2021-07-21
AU2019216724C1 (en)	2021-08-26
AR132009A2 (es)	2025-05-21
NZ630869A (en)	2017-11-24
CN105451763A (zh)	2016-03-30
NO2023026I1 (no)	2023-07-04
UY35489A (es)	2014-10-31
WO2014150939A2 (en)	2014-09-25
EP4129330A1 (en)	2023-02-08
CA3177572A1 (en)	2014-09-25
CA3177574A1 (en)	2014-09-25
BR122021015502A2 (pt)	2021-12-14
MX2023000349A (es)	2023-04-24
DK4129330T5 (da)	2024-07-22
MX2023000354A (es)	2023-02-13
LTPA2024503I1 (hu)	2024-03-25
CN105451763B (zh)	2021-06-18
LT4129330T (lt)	2023-12-27
JP7050031B2 (ja)	2022-04-07
TWI894248B (zh)	2025-08-21
CN113637086A (zh)	2021-11-12
CN111778263B (zh)	2024-07-26
KR20240014580A (ko)	2024-02-01
US20230181682A1 (en)	2023-06-15
TWI726312B (zh)	2021-05-01
ECSP23013715A (es)	2023-04-28
BR112015023635A2 (pt)	2018-06-05
CN113637694B (zh)	2024-11-12
KR102389908B1 (ko)	2022-04-26
PH12015502120A1 (en)	2016-01-25
EP4183411A1 (en)	2023-05-24
CN113637693A (zh)	2021-11-12
KR20160002780A (ko)	2016-01-08
US20250018006A1 (en)	2025-01-16
BR122021015503A2 (pt)	2021-12-14
ES2933970T3 (es)	2023-02-15
EP3689374B1 (en)	2022-11-02
EP3689374A1 (en)	2020-08-05
HUE061507T2 (hu)	2023-07-28
MX2023000353A (es)	2023-02-13
US20140302088A1 (en)	2014-10-09
CA3166063A1 (en)	2014-09-25
SG10201913435TA (en)	2020-03-30
JP2016513970A (ja)	2016-05-19
FIC20230021I1 (fi)	2023-06-27
FI3539565T3 (fi)	2023-04-19
EP2968516A2 (en)	2016-01-20
AR133264A2 (es)	2025-09-10
KR102626270B1 (ko)	2024-01-19
CN113637694A (zh)	2021-11-12
EP2968516B1 (en)	2022-01-12
KR102775714B1 (ko)	2025-03-06
HK1220359A1 (zh)	2017-05-05
CN111778263A (zh)	2020-10-16
AR123702A2 (es)	2023-01-04
PT3539565T (pt)	2023-04-12
FR22C1064I2 (fr)	2024-12-13
US20200061151A1 (en)	2020-02-27
US20220062375A1 (en)	2022-03-03
MX374519B (es)	2025-03-06
MX2019003602A (es)	2022-06-27
TW201516147A (zh)	2015-05-01
CR20150569A (es)	2016-04-01
CA2903231C (en)	2025-12-09
TW201945545A (zh)	2019-12-01
AU2014235476B2 (en)	2019-05-16
EP4129330B1 (en)	2023-09-06
AU2014235476A1 (en)	2015-09-24
MX2015012893A (es)	2016-04-04
CN113637086B (zh)	2024-10-11
AR095598A1 (es)	2015-10-28
TW202144573A (zh)	2021-12-01
HRP20231581T1 (hr)	2024-03-15
DK4129330T3 (da)	2023-12-11
JP2019146594A (ja)	2019-09-05
PH12015502120B1 (en)	2024-02-16
PL3539565T3 (pl)	2023-09-25
SG10201913387XA (en)	2020-02-27
US10449231B2 (en)	2019-10-22
BR112015023635A8 (pt)	2021-12-14
US11931399B2 (en)	2024-03-19
DOP2015000232A (es)	2016-02-29
ES2965652T3 (es)	2024-04-16
FR22C1064I1 (fr)	2023-02-03

Publication	Publication Date	Title
HUS2300022I1 (hu)	2023-08-28	Készítmények és eljárások vakcinák dengue vírus kiméra-konstrukcióihoz
IL285780A (en)	2021-09-30	Tmprss6 irna compositions and methods of use thereof
IL289821B (en)	2022-12-01	Compositions and methods for immunotherapy
IL242394B (en)	2019-05-30	Cenicriviroc compositions and methods of making and using the same
IL258434A (en)	2018-05-31	Haploid induction compositions and methods for use therefor
HUE051982T2 (hu)	2021-04-28	Anti-alfa-szinuklein antitestek és alkalmazási eljárások
IL240472A0 (en)	2015-09-24	Chimeric antigen receptor and methods of use thereof
DK3052516T3 (da)	2020-03-23	PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
SG11201606624WA (en)	2016-09-29	Antibody moleules to dengue virus and uses thereof
HUE059701T2 (hu)	2022-12-28	Antitestek és felhasználási módszerek
IL285527A (en)	2021-09-30	Compositions and methods for immunotherapy
HUE057726T2 (hu)	2022-06-28	Fehérje glikozilálására szolgáló készítmények és módszerek
ZA201509229B (en)	2022-03-30	Influenza virus vaccines and uses thereof
IL240936B (en)	2019-11-28	Reassortment of influenza virus and methods for their preparation
HUE053033T2 (hu)	2021-06-28	Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
HUE046673T2 (hu)	2020-03-30	Anti-EpCAM antitestek és alkalmazási eljárások
SG11201703366RA (en)	2017-05-30	Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
SG11201510266SA (en)	2016-01-28	Dengue virus vaccine compositions and methods of use thereof
SG11201510617WA (en)	2016-01-28	Methods and compositions for dengue virus vaccines
SG11201704942QA (en)	2017-07-28	Dengue virus vaccine compositions and methods of use thereof
EP2996718A4 (en)	2017-06-21	E1e2 hcv vaccines and methods of use
SG11201606237RA (en)	2016-09-29	Hcv chimeric vaccine with influenza virus as vector and preparation method thereof
EP2968394A4 (en)	2016-04-20	NEW VACCINES AGAINST MULTIPLE SUBTYPES OF THE DENGUE VIRUS
IL240514A0 (en)	2015-10-29	Pharmaceutical compositions containing dexketoprofen and tramadol
AP2015008881A0 (en)	2015-11-30	Vaccines for diseases caused by viruses of the family of reoviridae